Minerva Neurosciences Shares Outstanding History (NERV)
Minerva Neurosciences reported 43.3M shares outstanding at the end of fiscal 2025.
View full Minerva Neurosciences company overviewMinerva Neurosciences annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 43.3M | 36.3M | +518.79% |
| 2024 | 2024-12-31 | 7.0M | 0 | 0.00% |
| 2023 | 2023-12-31 | 7.0M | 1.7M | +30.96% |
| 2022 | 2022-12-31 | 5.3M | −3 | −0.00% |
| 2021 | 2021-12-31 | 5.3M | −37.4M | −87.50% |
| 2020 | 2020-12-31 | 42.7M | 3.6M | +9.31% |
| 2019 | 2019-12-31 | 39.1M | 146,150 | +0.38% |
| 2018 | 2018-12-31 | 38.9M | 188,628 | +0.49% |
| 2017 | 2017-12-31 | 38.7M | 3.7M | +10.64% |
| 2016 | 2016-12-31 | 35.0M | 10.3M | +41.68% |
| 2015 | 2015-12-31 | 24.7M | 6.3M | +34.07% |
| 2014 | 2014-12-31 | 18.4M | 12.3M | +201.66% |
| 2013 | 2013-12-31 | 6.1M | — | — |
Minerva Neurosciences quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 47.2M | 40.2M | +575.31% |
| Q1 2026 | 2026-03-31 | 43.8M | 36.8M | +526.90% |
| Q4 2025 | 2025-12-31 | 43.3M | 36.3M | +518.79% |
| Q3 2025 | 2025-09-30 | 7.0M | 0 | 0.00% |
| Q2 2025 | 2025-06-30 | 7.0M | 0 | 0.00% |
| Q1 2025 | 2025-03-31 | 7.0M | 0 | 0.00% |
| Q4 2024 | 2024-12-31 | 7.0M | 0 | 0.00% |
| Q3 2024 | 2024-09-30 | 7.0M | 0 | 0.00% |
| Q2 2024 | 2024-06-30 | 7.0M | 0 | 0.00% |
| Q1 2024 | 2024-03-31 | 7.0M | 1.7M | +30.96% |
| Q4 2023 | 2023-12-31 | 7.0M | 1.7M | +30.96% |
| Q3 2023 | 2023-09-30 | 7.0M | 1.7M | +30.96% |
| Q2 2023 | 2023-06-30 | 7.0M | 1.7M | +30.96% |
| Q1 2023 | 2023-03-31 | 5.3M | −37.4M | −87.50% |
| Q4 2022 | 2022-12-31 | 5.3M | −37.4M | −87.50% |
| Q3 2022 | 2022-09-30 | 5.3M | −37.4M | −87.50% |
| Q2 2022 | 2022-06-30 | 5.3M | −37.4M | −87.50% |
| Q1 2022 | 2022-03-31 | 42.7M | 0 | 0.00% |
| Q4 2021 | 2021-12-31 | 42.7M | 0 | 0.00% |
| Q3 2021 | 2021-09-30 | 42.7M | 47,075 | +0.11% |
| Q2 2021 | 2021-06-30 | 42.7M | 2.1M | +5.11% |
| Q1 2021 | 2021-03-31 | 42.7M | 3.5M | +8.93% |
| Q4 2020 | 2020-12-31 | 42.7M | 3.6M | +9.31% |
| Q3 2020 | 2020-09-30 | 42.7M | 3.6M | +9.35% |
| Q2 2020 | 2020-06-30 | 40.6M | 1.6M | +4.15% |
| Q1 2020 | 2020-03-31 | 39.2M | 193,663 | +0.50% |
| Q4 2019 | 2019-12-31 | 39.1M | 146,150 | +0.38% |
| Q3 2019 | 2019-09-30 | 39.0M | 179,004 | +0.46% |
| Q2 2019 | 2019-06-30 | 39.0M | 276,128 | +0.71% |
| Q1 2019 | 2019-03-31 | 39.0M | 276,128 | +0.71% |
| Q4 2018 | 2018-12-31 | 38.9M | 188,628 | +0.49% |
| Q3 2018 | 2018-09-30 | 38.8M | 145,774 | +0.38% |
| Q2 2018 | 2018-06-30 | 38.7M | 2.0M | +5.41% |
| Q1 2018 | 2018-03-31 | 38.7M | 2.0M | +5.57% |
| Q4 2017 | 2017-12-31 | 38.7M | 3.7M | +10.64% |
| Q3 2017 | 2017-09-30 | 38.7M | 3.9M | +11.19% |
| Q2 2017 | 2017-06-30 | 36.8M | 2.0M | +5.61% |
| Q1 2017 | 2017-03-31 | 36.7M | 8.8M | +31.36% |
| Q4 2016 | 2016-12-31 | 35.0M | 10.3M | +41.68% |
| Q3 2016 | 2016-09-30 | 34.8M | 10.1M | +40.80% |
| Q2 2016 | 2016-06-30 | 34.8M | 10.1M | +40.79% |
| Q1 2016 | 2016-03-31 | 27.9M | 3.2M | +13.03% |
| Q4 2015 | 2015-12-31 | 24.7M | 6.3M | +34.07% |
| Q3 2015 | 2015-09-30 | 24.7M | 6.3M | +34.07% |
| Q2 2015 | 2015-06-30 | 24.7M | 16.2M | +190.12% |
| Q1 2015 | 2015-03-31 | 24.7M | 18.6M | +304.42% |
| Q4 2014 | 2014-12-31 | 18.4M | — | — |
| Q3 2014 | 2014-09-30 | 18.4M | — | — |
| Q2 2014 | 2014-06-30 | 8.5M | — | — |
| Q4 2013 | 2013-12-31 | 6.1M | — | — |
Minerva Neurosciences shares outstanding trends
Over the last five reported fiscal years, Minerva Neurosciences's shares outstanding moved from 42.7M to 43.3M, a change of 552,832. The latest reported quarter, Q2 2026, shows 47.2M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Minerva Neurosciences filings at SEC.gov ↗